Growth & profitability
- Revenue has declined 26.6% per year over the past 5 years.
APVO Financials Aptevo Therapeutics Inc.
11 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
ROEROA
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | — | -$26M | — | — | -149.4% | -95.5% | — | — | $22M |
| 2024 | — | -$24M | — | — | -507.5% | -154.8% | — | — | $9M |
| 2023 | — | -$17M | — | — | -142.5% | -70.1% | — | $0 | $17M |
| 2022 | $3M | $8M | 0.0% | -919.7% | 44.7% | 23.5% | -$21M | $4M | $23M |
| 2021 | $12M | -$28M | 0.0% | -174.1% | -2340.2% | -50.3% | -$22M | $16M | $45M |
| 2020 | $4M | -$18M | 0.0% | -638.1% | -107.0% | -33.1% | -$29M | $28M | $40M |
| 2019 | $32M | -$40M | 38.5% | -126.3% | -341.6% | -75.7% | -$43M | — | $12M |
| 2018 | $23M | -$54M | 51.4% | -224.0% | -176.6% | -79.5% | -$52M | $19M | $31M |
| 2017 | $15M | $7M | 0.0% | -368.1% | 8.5% | 6.0% | -$43M | $19M | $7M |
| 2016 | — | -$112M | — | — | -222.3% | -122.4% | — | $18M | $10M |
| 2015 | — | -$59M | — | — | -66.9% | -46.4% | — | — | $5M |
RevenueNet income
GrossOperatingNet
ROEROA
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| Jun '26 | — | -$6M | — | — | -105.2% | -43.8% | — | — | $10M |
| Mar '26 | — | -$7M | — | — | -57.7% | -33.6% | — | — | $15M |
| Dec '25 | — | -$6M | — | — | -33.4% | -21.4% | — | — | $22M |
| Sep '25 | — | -$8M | — | — | -43.4% | -28.0% | — | — | $21M |
| Jun '25 | — | -$6M | — | — | -95.1% | -39.7% | — | — | $9M |
| Mar '25 | — | -$6M | — | — | 435.0% | -76.8% | — | — | $2M |
| Dec '24 | — | -$6M | — | — | -132.7% | -40.5% | — | — | $9M |
| Sep '24 | — | -$5M | — | — | -115.4% | -33.7% | — | — | $8M |
| Jun '24 | — | -$6M | — | — | -131.8% | -39.4% | — | — | $8M |
| Mar '24 | — | -$7M | — | — | -112.0% | -38.8% | — | — | $10M |
| Dec '23 | — | -$6M | — | — | -48.3% | -23.8% | — | $0 | $17M |
| Sep '23 | — | -$6M | — | — | -43.0% | -23.3% | — | $0 | $19M |
| Jun '23 | — | -$8M | — | — | -48.9% | -27.5% | — | $0 | $21M |
| Mar '23 | — | $3M | — | — | 11.9% | 7.9% | — | $0 | $25M |
| Dec '22 | $0 | -$5M | — | — | -25.8% | -13.6% | -$6M | $4M | $23M |
| Sep '22 | $0 | -$8M | — | — | -48.5% | -24.1% | -$7M | $4M | $22M |
| Jun '22 | $0 | $28M | — | — | 121.5% | 72.2% | — | — | $29M |
| Mar '22 | $3M | -$8M | 0.0% | -180.2% | 130.8% | -17.0% | — | — | $35M |
| Dec '21 | $4M | -$6M | 0.0% | -110.2% | -515.8% | -11.1% | -$4M | $16M | $45M |
| Sep '21 | $3M | -$7M | 0.0% | -153.4% | -96.0% | -10.9% | -$5M | — | $52M |
Valuation over time
How the market has priced APVO against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-earnings ratio has fallen from 9.6× (Mar '23) to 1.3× (Oct '23).
- The price-to-sales ratio has fallen from 24.7× (Mar '23) to 2.2× (Dec '23).
P/E
P/S
Frequently asked questions
Is APVO growing its revenue and profit?
Over the past 5 years, Aptevo Therapeutics Inc.'s revenue has declined 26.6% per year. These are computed facts, not advice.
How much debt does APVO have?
As of FY2025, Aptevo Therapeutics Inc. reported — of total debt against $22M of cash.
What is APVO's profit margin?
In FY2025, gross margin was —, operating margin —, and net margin —.
What is APVO's P/E ratio?
As of Sep '26, Aptevo Therapeutics Inc. traded at a price-to-earnings ratio of about 1.3× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.